Ascentage Pharma Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
567
- Stock Symbol
-
06855
- Investments
-
3
- Share Price
-
$5.87
- (As of Monday Closing)
Ascentage Pharma General Information
Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
Contact Information
Website
www.ascentage.cnCorporate Office
- 68 Xinqing Road
- Suzhou Industrial Park
- Suzhou, Jiangsu 215000
- China
Corporate Office
- 68 Xinqing Road
- Suzhou Industrial Park
- Suzhou, Jiangsu 215000
- China
Ascentage Pharma Timeline
Ascentage Pharma Stock Performance
As of 19-May-2025, Ascentage Pharma’s stock price is $5.87. Its current market cap is $2.05B with 348M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.87 | $5.75 | $2.17 - $6.79 | $2.05B | 348M | 4.22M | -$0.19 |
Ascentage Pharma Financials Summary
As of 31-Dec-2024, Ascentage Pharma has a trailing 12-month revenue of $137M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,933,266 | 1,933,266 | 1,027,314 | 848,823 |
| Revenue | 136,667 | 136,667 | 31,376 | 31,140 |
| EBITDA | (38,391) | (38,391) | (109,687) | (115,999) |
| Net Income | (56,503) | (56,503) | (130,834) | (131,104) |
| Total Assets | 358,599 | 358,599 | 352,734 | 410,224 |
| Total Debt | 228,558 | 228,558 | 253,307 | 259,842 |
Ascentage Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ascentage Pharma Comparisons
Industry
Financing
Details
Ascentage Pharma Competitors (23)
One of Ascentage Pharma’s 23 competitors is Transcenta Holding, a Formerly VC-backed company based in Suzhou, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Transcenta Holding | Formerly VC-backed | Suzhou, China | ||||
| Gilead Sciences | Formerly VC-backed | Foster City, CA | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| ENCEFA | Corporation | Saint Maur Des Fosses, France |
Ascentage Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ascentage Pharma Patents
Ascentage Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4490159-A1 | Tricyclic heterocycle compounds as iap antagonists | Pending | 11-Mar-2022 | ||
| US-20250152580-A1 | Methods for treating immune diseases | Pending | 07-Mar-2022 | ||
| EP-4471031-A1 | Crystalline form or amorphous form of macrocyclic compound or salt or solvate thereof | Pending | 30-Jan-2022 | ||
| US-20250109134-A1 | Crystalline form or amorphous form of macrocyclic compound or salt or solvate thereof | Pending | 30-Jan-2022 | ||
| US-20250114329-A1 | Methods for treating aml-mrc and mds | Pending | 11-Jan-2022 | A61K31/407 |
Ascentage Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ascentage Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Ascentage Pharma Investments & Acquisitions (3)
Ascentage Pharma’s most recent deal was a Early Stage VC with Inhal Pharma. The deal was made on 23-Feb-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Inhal Pharma | 23-Feb-2024 | Early Stage VC | Drug Delivery | ||
| Healthquest Pharma | 01-Dec-2016 | Merger/Acquisition | Therapeutic Devices | ||
| Joint Venture (Ascentage Pharma and Unity Biotechnology) | 01-Feb-2016 | Joint Venture | Media and Information Services (B2B) |
Ascentage Pharma ESG
Risk Overview
Risk Rating
Updated November, 30, 2024
33.1 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Biotechnology
Subindustry
of 365
Rank
Percentile
Ascentage Pharma Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Healthquest Pharma | Guangzhou, China | 2012 |
Ascentage Pharma FAQs
-
When was Ascentage Pharma founded?
Ascentage Pharma was founded in 2009.
-
Where is Ascentage Pharma headquartered?
Ascentage Pharma is headquartered in Suzhou, China.
-
What is the size of Ascentage Pharma?
Ascentage Pharma has 567 total employees.
-
What industry is Ascentage Pharma in?
Ascentage Pharma’s primary industry is Drug Discovery.
-
Is Ascentage Pharma a private or public company?
Ascentage Pharma is a Public company.
-
What is Ascentage Pharma’s stock symbol?
The ticker symbol for Ascentage Pharma is 06855.
-
What is the current stock price of Ascentage Pharma?
As of 19-May-2025 the stock price of Ascentage Pharma is $5.87.
-
What is the current market cap of Ascentage Pharma?
The current market capitalization of Ascentage Pharma is $2.05B.
-
What is Ascentage Pharma’s current revenue?
The trailing twelve month revenue for Ascentage Pharma is $137M.
-
Who are Ascentage Pharma’s competitors?
Transcenta Holding, Gilead Sciences, Novartis, Regeneron Pharmaceuticals, and ENCEFA are some of the 23 competitors of Ascentage Pharma.
-
What is Ascentage Pharma’s annual earnings per share (EPS)?
Ascentage Pharma’s EPS for 12 months was -$0.19.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
